Non-viral methods for gene transfer towards osteosarcoma therapy

Abstract

Osteosarcoma, a class of cancer that originates from bone, afflicts mainly young people usually in their teenage years of life. Despite surgery and chemotherapy, the outlook for sufferers is not that positive, with a third of patients with metastatic disease not surviving past the 10-year mark. Like other neoplasms, other forms of therapeutics are being evaluated, and amongst these is gene therapy. This review discusses approaches for gene therapy of osteosarcoma using cationic liposomes and polyethylenimine in vivo. The field is still in its infancy as far as osteosarcoma is concerned and much more needs to be done to test its true potential as a feasible therapeutic modality.

The Various Roles of PEDF in Cancer

“…The domain of gene therapy has a history spanning two decades, tracing its roots in the late 1980s when gene manipulation in mammalian cells was first explored [154][155][156]. Around the year 2000, gene therapy achieved its initial breakthroughs, particularly in the highly specialised domain of addressing severe inherited T-cell immune deficiencies through ex vivo gene transfer into hematopoietic stem (HS) or progenitor cells (C) [157].…”

PK11195-chitosan-graft-polyethylenimine-modified SPION as a mitochondria-targeting gene carrier

“…For decades, gene therapy has been investigated as a potential treatment for cancers [1][2][3][4]. The feasibility of gene therapy depends on the successful delivery of therapeutic gene to the tumor lesions, which promotes the pursuit of a safe and efficient gene vector [5][6][7].…”